Scorpion Therapeutics is a startup operating in the biotechnology sector, specifically focusing on the development of precision oncology treatments. The company's mission is to deliver fast, precise, and lethal strikes against unique cancer drivers. They do this by developing drugs specifically designed to interact with validated cancer targets, optimizing their selectivity and pharmaceutical properties to improve safety and efficacy.

Scorpion Therapeutics serves a broad market, including healthcare providers, cancer patients, and pharmaceutical companies. Their clients are those seeking innovative and effective cancer treatments, and their market is global, given the universal nature of cancer.

The business model of Scorpion Therapeutics is based on research and development of new drugs, followed by partnerships with larger pharmaceutical companies for distribution and sales. A recent example of this is their partnership with Pierre Fabre, where they prioritized investment in a third asset. This model allows Scorpion Therapeutics to focus on what they do best - developing innovative cancer treatments - while leveraging the resources and distribution networks of established pharmaceutical companies.

Scorpion Therapeutics generates revenue through these partnerships, either through upfront payments, milestone payments based on the progress of drug development, or royalties from the sales of the drugs they develop.

The company prides itself on its world-class team of experts in various fields, including cancer biology, medicinal chemistry, chemical proteomics, computational chemistry, molecular biophysics, machine learning, and drug development. They also place a high value on their work culture, seeking team members who share their cultural commitments.

Keywords: Biotechnology, Precision Oncology, Cancer Treatment, Drug Development, Pharmaceutical Partnerships, Cancer Biology, Medicinal Chemistry, Chemical Proteomics, Computational Chemistry, Molecular Biophysics.